.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Deloitte
Julphar
Moodys
Healthtrust
Merck
Boehringer Ingelheim
Accenture
Colorcon
AstraZeneca

Generated: December 15, 2017

DrugPatentWatch Database Preview

NAMENDA Drug Profile

« Back to Dashboard

When do Namenda patents expire, and what generic alternatives are available?

Namenda is a drug marketed by Forest Labs Llc and is included in three NDAs. There are seven patents protecting this drug and five Paragraph IV challenges.

The generic ingredient in NAMENDA is memantine hydrochloride. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the memantine hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-004Jun 21, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-004Jun 21, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-004Jun 21, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-004Jun 21, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Forest Labs LlcNAMENDAmemantine hydrochlorideSOLUTION;ORAL021627-001Apr 18, 2005AARXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-002Jun 21, 2010ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-003Jun 21, 2010ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-001Jun 21, 2010ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-004Jun 21, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-001Jun 21, 2010ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NAMENDA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs LlcNAMENDAmemantine hydrochlorideSOLUTION;ORAL021627-001Apr 18, 2005► Subscribe► Subscribe
Forest Labs LlcNAMENDAmemantine hydrochlorideTABLET;ORAL021487-002Oct 16, 2003► Subscribe► Subscribe
Forest Labs LlcNAMENDAmemantine hydrochlorideTABLET;ORAL021487-001Oct 16, 2003► Subscribe► Subscribe
Forest Labs LlcNAMENDAmemantine hydrochlorideTABLET;ORAL021487-002Oct 16, 2003► Subscribe► Subscribe
Forest Labs LlcNAMENDAmemantine hydrochlorideTABLET;ORAL021487-001Oct 16, 2003► Subscribe► Subscribe
Forest Labs LlcNAMENDAmemantine hydrochlorideSOLUTION;ORAL021627-001Apr 18, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for NAMENDA

Drugname Dosage Strength RLD Submissiondate
memantine hydrochlorideTablets5 mg and 10 mgNamenda10/16/2007
memantine hydrochlorideExtended-release Capsules7 mg, 14 mg, 21 mg, and 28 mgNamenda XR6/10/2013
memantine hydrochlorideExtended-release Capsules7 mg, 14 mg, 21 mg, and 28 mgNamenda XR8/16/2013
memantine hydrochlorideExtended-release Capsules28 mgNamenda XR6/12/2013
memantine hydrochlorideExtended-release Capsules7 mg, 14 mg, 21 mgNamenda XR6/17/2013

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Chinese Patent Office
Novartis
Deloitte
Mallinckrodt
Covington
US Army
UBS
Cipla
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot